TrialCancer medicine2017
Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
Francine Foss et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
9 papers cite it
this papertrialcites it